The Patient You Almost Missed
You’ve seen this happen before.
Mrs. Kapoor, 58, living with type 2 diabetes, walks in for her routine foot exam.
You take out the monofilament and test all ten sites.
Every spot — she feels it.
You mark the box: “Protective sensation intact.”
She leaves, and you move on to the next case.
Fast forward three months. Mrs. Kapoor returns — this time with a deep ulcer on her heel.
“I never even felt it developing,” she says, bewildered. “But you said everything was fine?”
What went unnoticed was the real story: her large-fiber vibration sense was already deteriorating, and her small-fiber perception — hot and cold — had nearly vanished.
The monofilament only captured one piece of the puzzle.
The rest went unseen.
And that gap allowed a preventable ulcer to happen.
Sound familiar?
We Need to Talk About Our Assessment Protocols
Let’s be real about how diabetic foot assessments typically play out:
We lean almost entirely on the 10g monofilament test
Maybe grab a tuning fork—if it’s within reach
Temperature perception? Usually skipped
Small-fiber evaluation? Brushed off as “impractical”
And when it comes to integrating results? They’re buried in fragmented notes
This fragmented approach means we’re identifying neuropathy too late—when protective sensation is already gone, and irreversible damage has begun.
The International Working Group on the Diabetic Foot (IWGDF) calls for a comprehensive, multi-parameter assessment.
But the reality is—most clinics just don’t have the tools or the time.
That’s about to change.
Why Single-Domain Testing Falls Short
The Monofilament Limitation
The 10g monofilament test is simple, affordable, and clinically validated for detecting loss of protective sensation (LOPS). But here’s the catch — by the time a patient fails the monofilament test, significant nerve damage has already occurred.
Research shows that small-fiber neuropathy, which impairs pain and temperature perception, typically develops years before large-fiber involvement becomes evident. These early-stage patients often pass the monofilament test, giving a false sense of security — while their feet are already at risk of ulceration and long-term complications.
The Vibration Perception Gap
The tuning fork is highly operator-dependent. Your “strong vibration” might be different from The tuning fork is notoriously operator-dependent — what feels like a “strong vibration” to one clinician might register as “barely perceptible” to another. Consistency goes out the window.
On the other hand, quantitative vibration perception testing delivers objective, reproducible data. Yet, let’s be honest — most clinics have a biothesiometer sitting idle, gathering dust in a corner. Why? Because it’s one more standalone device to maintain, manage, and record from — adding friction to an already busy workflow.
The Small-Fiber Problem
Small-fiber nerves are responsible for mediating pain and temperature sensation — the body’s first line of defense against injury. When these nerves deteriorate:
Patients don’t sense burns or cold injuries
Early signs of tissue stress go unnoticed
Silent ischemia develops without symptoms
Charcot neuroarthropathy can advance undetected
Despite the clinical impact, small-fiber testing is rarely performed in routine practice. The reason is simple: traditional assessment methods are cumbersome, time-consuming, and poorly integrated into standard workflows.
The Thermal Asymmetry Insight
Temperature monitoring offers far more than a neuropathy check — it’s an early warning system for multiple limb-threatening complications.
A temperature difference of just 2°C between feet can indicate:
· Active Charcot neuroarthropathy
· Underlying inflammation
· Peripheral vascular compromise
· Early or hidden infection
Detecting these subtle asymmetries early can prevent irreversible deformities and foot collapse. Yet, let’s be honest — routine foot temperature measurement is still missing from most diabetic foot evaluations.
The Five Pillars of Comprehensive Foot Assessment
- Protective Sensation Testing (Monofilament)
- Vibration Perception Testing
- Hot Perception Testing
- Cold Perception Testing
- Infrared Thermometry
Why These Tests Work Together, Not in Isolation
Let’s look at what happens when you assess patients across multiple modalities.
Patient A
- Monofilament: Normal
- Vibration: Severely impaired
- Hot/Cold: Normal
- Temperature: Symmetric
Interpretation: Early large-fiber neuropathy. The patient may not perceive pressure or vibration — increasing the risk of callus formation and footwear injuries.
Patient B
- Monofilament: Normal
- Vibration: Mildly impaired
- Hot/Cold: Severely impaired
- Temperature: Symmetric
Interpretation: Small-fiber predominant neuropathy. The patient may not detect pain, heat, or cold — raising the risk of burns, unnoticed infections, or thermal injuries.
Patient C
- Monofilament: Abnormal
- Vibration: Abnormal
- Hot/Cold: Abnormal
- Temperature: 3°C asymmetry
Interpretation: Advanced neuropathy with active pathology (Charcot, infection, or inflammation possible). Requires immediate imaging and specialist intervention.
See the difference?
With monofilament testing alone, Patient A and Patient B would look the same — “normal sensation.”
But their neuropathy patterns, risk profiles, and management strategies are completely different.
The Integration Solution: NEURO TOUCH 5-in-1 Device
Let’s face it — comprehensive neuropathy assessment sounds ideal in theory, but in a busy clinic, nobody wants to juggle five separate tools for every diabetic foot exam.
Enter NEURO TOUCH by Yostra Labs
A single, portable, digital device that consolidates all key neuropathy assessments — giving you a complete, quantitative picture in under 10 minutes.
One Device. Five Integrated Tests
- Digital monofilament with calibrated force sensing
- Quantitative vibration perception (biothesiometer)
- Thermal perception – Hot
- Thermal perception – Cold
- Infrared skin temperature measurement
The Specs That Actually Matter
- Portable: 470 g — carry it between rooms or camps effortlessly
- Battery life: Up to 50 patient assessments per charge
- Speed: 8–10 minutes for all five domains
- Data: Bluetooth sync + cloud reports with automatic trending
- Accuracy: Digital sensors ensure zero operator bias
Implementation Guide for Your Practice
Step 1: Audit Your Current Protocol
Ask yourself:
- What % of diabetic patients get any form of foot assessment?
- Which tests are performed consistently?
- Where are the blind spots?
- How long does each assessment take?
- How are you tracking changes over time?
Reality check: Most clinics assess only 30–40% of eligible patients — and often with incomplete data.
Step 2: Train Your Team
Who can perform testing:
- Nurses
- Medical assistants
- Podiatry technicians
- Trained paramedics (for outreach)
Training essentials:
- Correct patient positioning
- Ambient temperature control (cold rooms distort results)
- Standardized test sequence
- Artifact recognition (e.g., calluses or vascular issues)
- Documentation + escalation protocols
Step 3: Optimize Workflow
Choose a model that fits your practice:
Option A — Intake Assessment (Efficient):
- Conduct during vitals collection
- Results ready for physician review
- Ideal for high-volume setups
Option B — Physician-Led (Engaging):
- Perform tests during consultation
- Enables immediate education and action
- Suits smaller clinics
Option C — Dedicated Visits (Thorough):
- Separate foot-check appointments
- Deep-dive evaluation for specialty centers
Step 4: Interpret Results Clinically
The system gives you clear numeric and color-coded outputs — your judgment gives them meaning.
Red Flags (Act Immediately):
- 2 °C asymmetry → image for Charcot/infection
- Absent sensation + ulcer history → urgent referral
- Rapid decline on serial tests → screen for secondary causes
Yellow Flags (Monitor Closely):
- Isolated small-fiber loss → tighten glycemic control
- Mild asymmetry → reinforce foot-check education
- Vibration loss only → gait/balance training, footwear correction
Green Zone (Stay Vigilant):
- All domains normal → annual recheck, preventive education
- Remember: Normal today doesn’t mean safe forever.
Step 5: Link Testing to Action
Data without action is wasted effort.
Every patient:
- Tailored foot-care education
- Written instructions + demonstration
Moderate risk:
- Proper footwear evaluation
- 6-month reassessment
- Glycemic optimization
- Physiotherapy for balance issues
High risk:
- Specialist podiatry referral
- 3-month reassessment
- Custom orthotics
- Vascular evaluation
- Consider continuous temp-monitoring devices
Step 6: Integrate with Your EMR
Don’t let results live in silos.
- Export NEURO TOUCH PDF reports into the EMR
- Tag high-risk patients
- Set recall reminders based on risk tier
- Close the loop from screening → action → follow-up
Step 7: Track Outcomes
Key metrics to monitor:
- % of diabetics assessed
- Risk distribution (low/moderate/high)
- New ulcer incidence
- Hospitalization rate
- Amputation rate
Within 12–24 months, you’ll see the curve shift:
✅ More high-risk cases detected early
✅ Timely interventions
✅ Measurable reduction in amputations
NEURO TOUCH bridges the gap between quick checks and comprehensive care — helping you move from reactive wound management to proactive nerve preservation.
Overcoming Common Objections
Objection 1: “We’re already overwhelmed. We don’t have time.”
Reality: NEURO TOUCH saves time.
One device. One session. One automated report.
Your current setup — monofilament, tuning fork, thermometer, manual notes — takes longer and yields fragmented data.
Try this: Pilot with one provider for one month.
Track the actual time spent per patient. You’ll be surprised how much smoother it gets when everything’s in one workflow.
Objection 2: “Our patients won’t sit through 10 minutes of testing.”
Response: When you tell them it’s about preventing ulcers and amputations, they absolutely will.
Patients value anything that helps them avoid complications.
Pro tip: Show them their digital report — color-coded and visual.
They’ll engage more when they can see what’s happening to their nerves.
Objection 3: “Monofilament is the standard of care. Why change what works?”
Response: Is it really working?
How many ulcers in your clinic “shouldn’t have happened” according to that monofilament check?
The truth — it only detects late-stage neuropathy.
The landscape has changed.
Clinical guidelines now emphasize comprehensive, multi-parameter assessment — not single-test screening.
Objection 4: “The device costs too much.”
Response: Not when you do the math.
It replaces five different tools, eliminates manual reporting, and cuts testing time in half.
The ROI comes from time saved, ulcers prevented, and outcomes improved.
Budget-sensitive? Start with the Lite version — get core assessments, then upgrade once you see the clinical and operational value.
Objection 5: “We’ll just refer complex cases to specialists.”
Reality: By the time you refer them, it’s often too late.
This device helps you catch neuropathy early, when preventive care can still make the difference.
Bonus: Specialists are overloaded.
They’ll appreciate well-documented, risk-stratified referrals — not late-stage ulcers.
Bottom line: NEURO TOUCH isn’t “one more thing” to do — it’s a smarter, faster way to do what you’re already doing, with fewer gaps and better outcomes.
Connect with Yostra Labs
Ready to bring comprehensive diabetic foot assessment to your practice?
Request a demo or consultation: Visit the Yostra Labs website or reach out to their clinical team. Mention this article to discuss implementation strategies specific to your practice setting.
For larger healthcare systems: Ask about bulk procurement and training programs.
Because your diabetic patients deserve more than a checkbox.
They deserve comprehensive care. And you deserve the tools to provide it.
References
- Armstrong DG, Boulton AJM, Bus SA. Diabetic Foot Ulcers and Their Recurrence. New England Journal of Medicine. 2017;376(24):2367-2375.
https://www.nejm.org/doi/full/10.1056/NEJMra1615439 - Paisey RB, Abbott A, Levenson R, et al. Diabetes-related major lower limb amputation incidence is strongly related to diabetic foot service provision and improves with enhancement of services: peer review of the South-West of England. Diabetic Medicine. 2018;35(1):53-62.
https://onlinelibrary.wiley.com/doi/full/10.1111/dme.13512 - Vas PRJ, Papanas N, Manu C, et al. Neuropad for assessment for diabetic peripheral neuropathy in patients with diabetes: A cost-effective study from India. Diabetes Research and Clinical Practice. 2020;160:108008.
https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(20)30034-9/fulltext - Perkins BA, Orszag A, Ngo M, et al. Prediction of incident diabetic neuropathy using the monofilament examination: a 4-year prospective study. Diabetes Care. 2010;33(7):1549-1554.
https://diabetesjournals.org/care/article/33/7/1549/29086/Prediction-of-Incident-Diabetic-Neuropathy-Using - Sharma S, Kerry C, Atkins H, Rayman G. The Ipswich Touch Test: a simple and novel method to assess patients with diabetes at home for increased risk of foot ulceration. Diabetic Medicine. 2014;31(9):1100-1103.
https://onlinelibrary.wiley.com/doi/full/10.1111/dme.12450 - Raputova J, Srotova I, Vlckova E, et al. Sensory phenotype and risk factors for painful diabetic neuropathy: a cross-sectional observational study. Pain. 2017;158(12):2340-2353.
https://journals.lww.com/pain/fulltext/2017/12000/sensory_phenotype_and_risk_factors_for_painful.13.aspx - Lavery LA, Higgins KR, Lanctot DR, et al. Preventing Diabetic Foot Ulcer Recurrence in High-Risk Patients: Use of temperature monitoring as a self-assessment tool. Diabetes Care. 2007;30(1):14-20.
https://diabetesjournals.org/care/article/30/1/14/28814/Preventing-Diabetic-Foot-Ulcer-Recurrence-in-High
